Opiant Pharmaceuticals Inc - Strategy, SWOT and Corporate Finance Report

Opiant Pharmaceuticals Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction and eating disorders. It focuses on developing treatments to reverse opioid overdoses, for overweight and obese patients with binge eating disorder (BED), and for cocaine use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant developed NARCAN (naloxone hydrochloride) nasal spray, a treatment to reverse opioid overdose. The product is approved for marketing in the US by its partner, Adapt Pharma. The company is also developing opioid antagonists with a near term focus on cocaine use disorder, binge eating disorder (BED) and bulimia nervosa. Opiant is headquartered in Santa Monica, California, the US.

Scope

  • Detailed information on Opiant Pharmaceuticals Inc required for business and competitor intelligence needs
  • A study of the major internal and external factors affecting Opiant Pharmaceuticals Inc in the form of a SWOT analysis
  • An in-depth view of the business model of Opiant Pharmaceuticals Inc including a breakdown and examination of key business segments
  • News about Opiant Pharmaceuticals Inc, such as business expansion, restructuring, and contract wins
  • Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

  • Gain understanding of Opiant Pharmaceuticals Inc and the factors that influence its strategies.
  • Track strategic initiatives of the company and latest corporate news and actions.
  • Assess Opiant Pharmaceuticals Inc as a prospective partner, vendor or supplier.
  • Support sales activities by understanding your customers' businesses better.
  • Stay up to date on Opiant Pharmaceuticals Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Shire Ltd

Orexo AB

Insys Therapeutics Inc

Indivior Plc

H. Lundbeck AS

Cerecor Inc

Camurus AB

BioDelivery Sciences International Inc

BioCorRx Inc

Alkermes Plc

Shire Ltd

Orexo AB

Insys Therapeutics Inc

Indivior Plc

H. Lundbeck AS

Cerecor Inc

Camurus AB

BioDelivery Sciences International Inc

BioCorRx Inc

Alkermes Plc

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Opiant Pharmaceuticals Inc - Key Facts

Opiant ...

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Opiant Pharmaceuticals Inc - Key Facts

Opiant Pharmaceuticals Inc - Key Employees

Opiant Pharmaceuticals Inc - Key Employee Biographies

Opiant Pharmaceuticals Inc - Major Products and Services

Opiant Pharmaceuticals Inc - History

Opiant Pharmaceuticals Inc - Company Statement

Opiant Pharmaceuticals Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Opiant Pharmaceuticals Inc - Business Description

Opiant Pharmaceuticals Inc - Corporate Strategy

Opiant Pharmaceuticals Inc - SWOT Analysis

SWOT Analysis - Overview

Opiant Pharmaceuticals Inc - Strengths

Opiant Pharmaceuticals Inc - Weaknesses

Opiant Pharmaceuticals Inc - Opportunities

Opiant Pharmaceuticals Inc - Threats

Opiant Pharmaceuticals Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Opiant Pharmaceuticals Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Nov 12, 2019: Opiant Pharmaceuticals reports third quarter 2019 financial results and provides corporate update

Oct 10, 2019: Opiant Pharmaceuticals to host a research & development meeting on emerging therapeutics for the treatment of addiction and drug overdose

Sep 17, 2019: Opiant Pharmaceuticals strengthens management team with appointments of Chief Commercial Officer and General Counsel

Aug 08, 2019: Opiant Pharmaceuticals reports second quarter 2019 financial results and provides corporate update

May 09, 2019: Opiant Pharmaceuticals reports first quarter 2019 financial results and provides corporate update

Mar 21, 2019: Opiant Pharmaceuticals reports fourth quarter and full-year 2018 financial results and provides corporate update

Dec 27, 2018: Opiant and Sanofi sign licensing deal for drinabant

Nov 07, 2018: Opiant Pharmaceuticals announces third quarter 2018 financial results

Oct 29, 2018: Opiant Pharmaceuticals names Craig Collard to Board of Directors

Sep 20, 2018: HHS sponsors development of intranasal form of long-acting opioid overdose drug

Section 6 – Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

Opiant Pharmaceuticals Inc, Key Facts

Opiant Pharmaceuticals Inc, Key Employees

Opiant Pharmaceuticals Inc, Key Employee Biographies

Opiant Pharmaceuticals Inc, Major Products and ...

List of Tables

Opiant Pharmaceuticals Inc, Key Facts

Opiant Pharmaceuticals Inc, Key Employees

Opiant Pharmaceuticals Inc, Key Employee Biographies

Opiant Pharmaceuticals Inc, Major Products and Services

Opiant Pharmaceuticals Inc, History

Opiant Pharmaceuticals Inc, Subsidiaries

Opiant Pharmaceuticals Inc, Key Competitors

Opiant Pharmaceuticals Inc, Ratios based on current share price

Opiant Pharmaceuticals Inc, Annual Ratios

Opiant Pharmaceuticals Inc, Annual Ratios (Cont...1)

Opiant Pharmaceuticals Inc, Annual Ratios (Cont...2)

Opiant Pharmaceuticals Inc, Interim Ratios

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Opiant Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Opiant Pharmaceuticals Inc, Performance Chart (2014 - 2018)

Opiant Pharmaceuticals Inc, Ratio Charts

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, ...

List of Figures

Opiant Pharmaceuticals Inc, Performance Chart (2014 - 2018)

Opiant Pharmaceuticals Inc, Ratio Charts

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports